Home/Alzamend Neuro/Andrew H. Woo

AH

Andrew H. Woo

Board Director

Therapeutic Areas

Alzheimer's Disease Bipolar Disorder Major Depressive Disorder Post-Traumatic Stress Disorder

Alzamend Neuro Pipeline

Drug	Indication	Phase
AL001	Bipolar Disorder	Phase II
ALZN002	Alzheimer's Disease	Preclinical

Leadership Team at Alzamend Neuro

Stephan Jackman

Lynne Fahey McGrath

Board Director, Audit Committee Chair

Thomas M. Wisniewski

Scientific Advisor

Scientific Advisor

Technology Transfer Advisor

View full Alzamend Neuro profile